Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pekka Tiikkainen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Chemical Information and Modeling|December 8, 2011
Analysis of commercial and public bioactivity databasesPekka Tiikkainen, Lutz Franke
Therapeutic Innovation & Regulatory Science|March 12, 2026
Enhancing Data Quality in Clinical Trials: Cross-Company Validation of the Open-Source Clinical Trial Anomaly Spotter (CTAS)Pekka Tiikkainen, Frederik Collin, Björn Koneswarakantha
Journal of Computer-Aided Molecular Design|December 4, 2008
Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screensPekka Tiikkainen, Antti Poso, Olli Kallioniemi
Journal of Chemical Information and Modeling|October 29, 2013
Estimating error rates in bioactivity databasesPekka Tiikkainen, Louisa Bellis, Yvonne Light, et al.
Future Medicinal Chemistry|June 29, 2011
Computational tools for polypharmacology and repurposingJanosch Achenbach, Pekka Tiikkainen, Lutz Franke, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 26, 2005
Distinct gene expression profiles in adult rat brains after acute MK-801 and cocaine treatmentsMarkus Storvik, Pekka Tiikkainen, Martijn van Iersel, et al.
Journal of Chemical Information and Modeling|October 6, 2009
Critical comparison of virtual screening methods against the MUV data setPekka Tiikkainen, Patrick Markt, Gerhard Wolber, et al.
Molecular Cancer Therapeutics|April 22, 2014
Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.NaJenni H E Mäki-Jouppila, Leena J Laine, Jonathan Rehnberg, et al.
Oncoscience|December 20, 2021
VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth <i>in vitro</i>Leena J Laine, Jenni H E Mäki-Jouppila, Emma Kutvonen, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Chemical Information and Modeling|December 8, 2011
Analysis of commercial and public bioactivity databasesPekka Tiikkainen, Lutz Franke
Therapeutic Innovation & Regulatory Science|March 12, 2026
Enhancing Data Quality in Clinical Trials: Cross-Company Validation of the Open-Source Clinical Trial Anomaly Spotter (CTAS)Pekka Tiikkainen, Frederik Collin, Björn Koneswarakantha
Journal of Computer-Aided Molecular Design|December 4, 2008
Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screensPekka Tiikkainen, Antti Poso, Olli Kallioniemi
Journal of Chemical Information and Modeling|October 29, 2013
Estimating error rates in bioactivity databasesPekka Tiikkainen, Louisa Bellis, Yvonne Light, et al.
Future Medicinal Chemistry|June 29, 2011
Computational tools for polypharmacology and repurposingJanosch Achenbach, Pekka Tiikkainen, Lutz Franke, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 26, 2005
Distinct gene expression profiles in adult rat brains after acute MK-801 and cocaine treatmentsMarkus Storvik, Pekka Tiikkainen, Martijn van Iersel, et al.
Journal of Chemical Information and Modeling|October 6, 2009
Critical comparison of virtual screening methods against the MUV data setPekka Tiikkainen, Patrick Markt, Gerhard Wolber, et al.
Molecular Cancer Therapeutics|April 22, 2014
Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.NaJenni H E Mäki-Jouppila, Leena J Laine, Jonathan Rehnberg, et al.
Oncoscience|December 20, 2021
VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth <i>in vitro</i>Leena J Laine, Jenni H E Mäki-Jouppila, Emma Kutvonen, et al.
Pageof 1